Cognition Therapeutics, Inc.
NASDAQ:CGTX
2.61 (USD) • At close September 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.266 | 0.252 | 0.235 | 0.093 | 0.098 | 0.081 |
| Gross Profit
| -0.266 | -0.252 | -0.235 | -0.093 | -0.098 | -0.081 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 41.676 | 37.196 | 30.324 | 18.572 | 12.887 | 14.379 |
| General & Administrative Expenses
| 12.29 | 13.528 | 13.227 | 10.026 | 4.52 | 3.452 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.29 | 13.528 | 13.227 | 10.026 | 4.52 | 3.452 |
| Other Expenses
| 0 | 0 | -0.235 | 0 | -0.098 | -13.164 |
| Operating Expenses
| 53.966 | 50.724 | 43.316 | 28.598 | 17.309 | 4.667 |
| Operating Income
| -53.966 | -50.724 | -43.551 | -28.598 | -17.407 | -17.831 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 19.995 | 24.936 | 22.154 | 16.882 | 9.568 | 0 |
| Income Before Tax
| -33.971 | -25.788 | -21.397 | -11.716 | -7.839 | -4.842 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -22.154 | -1.431 | 0 | 0 |
| Net Income
| -33.971 | -25.788 | 0.757 | -10.285 | -10.072 | -6.953 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.85 | -0.86 | -0.74 | -0.73 | -0.55 | -0.32 |
| EPS Diluted
| -0.85 | -0.86 | -0.74 | -0.73 | -0.55 | -0.32 |
| EBITDA
| -33.68 | -25.509 | -21.134 | -10.73 | -5.99 | -3.499 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |